A 58-year-old man with type 2 diabetes is on metformin and sitagliptin. His HbA1c is 8.4%, eGFR is 52 mL/min/1.73m², and he has established cardiovascular disease (prior MI). According to ADA 2024 guidelines, which agent should be PREFERENTIALLY added to reduce cardiovascular mortality in this patient?
- A Empagliflozin ✓
- B Pioglitazone
- C Glimepiride
- D Dulaglutide
Explanation
Empagliflozin (SGLT2 inhibitor) demonstrated a 38% reduction in cardiovascular death in the EMPA-REG OUTCOME trial, making it the preferred add-on agent in T2DM patients with established CVD who need intensification. The ADA 2024 Standards of Care recommend SGLT2 inhibitors or GLP-1 RA with proven CV benefit for patients with established ASCVD, regardless of HbA1c. Empagliflozin is safe down to eGFR 20 mL/min for CV benefit (glycemic effect requires higher eGFR). Glimepiride carries hypoglycemia risk without CV benefit; pioglitazone is second-line; dulaglutide (REWIND trial) also shows CV benefit but SGLT2i has additional HF/renal protection making it preferred here.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.